Trial reportMultiple sclerosis (Houndmills, Basingstoke, England)2018
Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.
Trial report in Multiple sclerosis (Houndmills, Basingstoke, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis.The Cochrane database of systematic reviews · 2024Pooled it
- Ocrelizumab for multiple sclerosis.The Cochrane database of systematic reviews · 2022Pooled it
- Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension.Journal of neurology · 2021Trial
- Mapping brain volume change across time in primary-progressive multiple sclerosis.Neuroradiology · 2024Article
- Impact of Ocrelizumab on Disease Progression, Memory Improvement, and Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal MRI and Clinical Criteria Analysis.Diseases (Basel, Switzerland) · 2024Article
- "Self-care selfies": Patient-uploaded videos capture meaningful changes in dexterity over 6 months.Annals of clinical and translational neurology · 2023Article
- Aging in multiple sclerosis: from childhood to old age, etiopathogenesis, and unmet needs: a narrative review.Frontiers in neurology · 2023Review
- Recurrent disability progression endpoints in multiple sclerosis clinical trials.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
- Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)-a systematic review protocol.Systematic reviews · 2022Article
- Ocrelizumab: A Review in Multiple Sclerosis.Drugs · 2022Review
- A Descriptive Correlational Study to Evaluate Three Measures of Assessing Upper Extremity Function in Individuals with Multiple Sclerosis.Multiple sclerosis international · 2021Article
- [Ocrelizumab for treatment of multiple sclerosis].Der Nervenarzt · 2020Review
- Impact of Age on Multiple Sclerosis Disease Activity and Progression.Current neurology and neuroscience reports · 2020Review
- Molecular Interventions towards Multiple Sclerosis Treatment.Brain sciences · 2020Review
- Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis.Multiple sclerosis international · 2020Article
- Can We Improve the Monitoring of People With Multiple Sclerosis Using Simple Tools, Data Sharing, and Patient Engagement?Frontiers in neurology · 2020Article
- Longitudinal assessment of hand function in individuals with multiple sclerosis.Multiple sclerosis and related disorders · 2019Article
- Epidemiology and treatment of multiple sclerosis in elderly populations.Nature reviews. Neurology · 2019Review
- Cladribine Tablets: A Review in Relapsing MS.CNS drugs · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUpper extremity (UE) impairment is common with primary progressive multiple sclerosis (PPMS).
objectiveThis exploratory analysis examined the effects of ocrelizumab on confirmed progression (CP) and confirmed improvement (CI) in UE impairment in patients from ORATORIO.
methodsPatients with PPMS received ocrelizumab 600 mg or placebo every 24 weeks for ⩾120 weeks. The Nine-Hole Peg Test (9HPT) was administered at baseline (BL) and every 12 weeks thereafter. Prespecified exploratory endpoints included change in 9HPT time and proportion of patients with CP of ⩾20% in 9HPT. Analysis populations included intention-to-treat (ITT) patients and subgroups stratified by BL 9HPT time and Expanded Disability Status Scale. Post hoc analyses included the proportion of patients achieving more severe thresholds of CP and the proportion achieving CI in 9HPT.
resultsAmong ITT patients, ocrelizumab significantly reduced the change in 9HPT time over 120 weeks, the risk of CP of ⩾20% in 9HPT time for both hands and the risk of more severe 9HPT progression versus placebo. Numerical trends also favoured ocrelizumab versus placebo with respect to achieving CI. Consistent directional trends were observed in subgroup analyses.
conclusionOcrelizumab reduces the risk of UE disability progression and may increase the possibility of improvement versus placebo in PPMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.